All News

podcast logo

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
backpain.hip_.jpg (keep)

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

Jack Cush, MD

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article
List.jpg (keep)

Day 4 - Top 3 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
kneepain3.jpg (keep)

Targeting the Wnt Pathway Fails in OA

RheumNow

The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast - COVID Kids and Men (5.15.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
FDA has issued draft guidance on Cannibis research: “Cannabis & Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” outlines FDA’s current thinking on clinical research related cannabis-derived compounds https://t.co/ppvisN1oxU

Links:

Dr. John Cush RheumNow ( View Tweet)

Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients (KL grade < 2) (HR 0.53), especially non-obese. Study from 1977 women in the Osteoarthritis Initiative. https://t.co/tZhovfMWTh

Links:

Dr. John Cush RheumNow ( View Tweet)

The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
2000–2016, analgesic use for OA has changed in UK. Oral NSAIDs Rx decreased & other analgesics/opioids increased (P < 0.001). Pts w/ GI dz likely to recv topical NSAIDs, tylenol, opioids. Opioids moreso in elderly, women, obesity, smokers, comorbidities. https://t.co/AJiWUAycLb

Links:

Dr. John Cush RheumNow ( View Tweet)

Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z

Links:

Dr. John Cush RheumNow ( View Tweet)

A negative RCT shows yearly treatment with Zolendronic acid fails to change tibiofemoral cartilage volume (by MRI) in Knee Osteoarthritis patients with bone marrow lesions. 223 knee OA pts recv ZOL vs PBO x24 mos , w/ no change inVAS pain (-11.5 vs -16.8) https://t.co/N7N0rL8iCX

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0327 AI stages knee OA radiograpgic chsnges ieth accuracy 91.8-99% in 95% of the cases. Would you prefer AI or human radiology readings for MSK imaging ? @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Hand OA Rx strikes out. HCQ Rx neg and colchicine Trial negative. I wouldn’t put hand OA as same category of no Rx as for SSc and Sjogrens but agree though nuts to crack @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/QRe3UpKpbz

Links:

Janet Pope Janetbirdope ( View Tweet)

Awesome colchicine data from @CatherineL_Hill @samwhittle and others: Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH) Abstract FRI0399 #EULAR2020 @RheumNow https://t.co/NVw9fo55dc https://t.co/LfHZVQTwIf

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk (vertebral & Maj OP Fx). 6144 infusions in 2594 pts, shows risk if delay is >16wks (long delay), but not if 4-16wks #EULAR20 SAT0453 https://t.co/DkJK3dHeRN https://t.co/r7ckpSF6PA

Links:

Dr. John Cush RheumNow ( View Tweet)
Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved OTC availability of Voltaren Gel - now called Voltaren Arthritis Pain: a topical NSAID, 1st approved by FDA in 2007. Indicated for the pain of osteoarthritis - It has not been effective in strains, sprains, bruises, sports injuries https://t.co/Tla75Bn4H0

Links:

Dr. John Cush RheumNow ( View Tweet)

1194 participants in Osteoarthritis Initiative shows 10 yr risk of incident Xray Knee OA was not increased by long term sitting, low-moderate physical activity (adjOR 0.69; 0.48-1.01) or strenuous phys activity (aOR 0.75; 0.53-1.07) https://t.co/7pCOwLpscr

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×